1258879-26-3

Upstream product

• 2941-78-8 2-Amino-5-methylbenzoic acid 
• 157834-02-1 2-ethyl-6-methyl-4H-benzo[d][1,3]oxazin-4-one 
• 130379-70-3 2-ethyl-6-methylquinazolin-4(3Η)-one 
• 536-90-3 m-Anisidine 
• 130379-71-4 6-Bromomethyl-2-ethyl-3H-quinazolin-4-one 

Relevant academic research and scientific papers

Fragment-Based Design of Novel Quinazolinon Derivatives as Human Acrosin Inhibitors

Human acrosin is a promising target for the male contraceptives. On the basis of the active site of human acrosin, a series of novel quinazolinon compounds were designed by a fragment docking and growing strategy. In vitro anti-acrosin assay revealed that all the compounds showed potent human acrosin inhibitory activities. In particular, compounds 5c and 5g are more active than the known inhibitors. Molecular docking studies revealed that the quinazolinon inhibitors interacted with human acrosin mainly through hydrogen bonding and hydrophobic interactions. The binding mode was also consistent with the structure-activity relationships. The quinazolinon derivatives in this study can serve as new lead structure for the development of novel male contraceptives. On the basis of the active site of human acrosin, a series of novel quinazolinon derivatives were designed and synthesized by a fragment docking and growing strategy. Compound 5g showed potent human acrosin inhibitory activity and was more active than the known inhibitors.